501 related articles for article (PubMed ID: 25832470)
1. Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study.
Buysman EK; Liu F; Hammer M; Langer J
Adv Ther; 2015 Apr; 32(4):341-55. PubMed ID: 25832470
[TBL] [Abstract][Full Text] [Related]
2. Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States.
Mody R; Huang Q; Yu M; Zhao R; Patel H; Grabner M; Landó LF
Diabetes Obes Metab; 2019 Apr; 21(4):920-929. PubMed ID: 30520248
[TBL] [Abstract][Full Text] [Related]
3. Predictors of glycemic control and diabetes-related costs among type 2 diabetes patients initiating therapy with liraglutide in the United States.
Durden E; Lenhart G; Lopez-Gonzalez L; Hammer M; Langer J
J Med Econ; 2016; 19(4):403-13. PubMed ID: 26653068
[TBL] [Abstract][Full Text] [Related]
4. Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation.
Yu M; Xie J; Fernandez Lando L; Kabul S; Swindle RW
Clin Ther; 2016 Jan; 38(1):149-60. PubMed ID: 26706658
[TBL] [Abstract][Full Text] [Related]
5. Persistence with Basal-Bolus Insulin Therapy in Patients with Type 2 Diabetes Mellitus and Effect on Clinical and Economic Outcomes: A Retrospective Claims Database Study.
Edelman SV; Ermakova A; Xiong Y; Sieradzan R; Taylor SD
J Manag Care Spec Pharm; 2019 Dec; 25(12):1420-1431. PubMed ID: 31550190
[TBL] [Abstract][Full Text] [Related]
6. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
Pelletier EM; Pawaskar M; Smith PJ; Best JH; Chapman RH
J Med Econ; 2012; 15(6):1039-50. PubMed ID: 22533526
[TBL] [Abstract][Full Text] [Related]
7. Real-world cost-effectiveness: lower cost of treating patients to glycemic goal with liraglutide versus exenatide.
DeKoven M; Lee WC; Bouchard J; Massoudi M; Langer J
Adv Ther; 2014 Feb; 31(2):202-16. PubMed ID: 24477354
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Early Response to GLP-1 RA Therapy on Long-Term Adherence and Persistence Among Type 2 Diabetes Patients in the United States.
Durden E; Liang M; Fowler R; Panton UH; Mocevic E
J Manag Care Spec Pharm; 2019 Jun; 25(6):669-680. PubMed ID: 30896359
[TBL] [Abstract][Full Text] [Related]
9. Retrospective Study on the Impact of Adherence in Achieving Glycemic Goals in Type 2 Diabetes Mellitus Patients Receiving Canagliflozin.
Buysman EK; Anderson A; Bacchus S; Ingham M
Adv Ther; 2017 Apr; 34(4):937-953. PubMed ID: 28251556
[TBL] [Abstract][Full Text] [Related]
10. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States.
Johnston SS; Nguyen H; Felber E; Cappell K; Nelson JK; Chu BC; Kalsekar I
Adv Ther; 2014 Nov; 31(11):1119-33. PubMed ID: 25408484
[TBL] [Abstract][Full Text] [Related]
11. Effect of V-Go Versus Multiple Daily Injections on Glycemic Control, Insulin Use, and Diabetes Medication Costs Among Individuals with Type 2 Diabetes Mellitus.
Raval AD; Nguyen MH; Zhou S; Grabner M; Barron J; Quimbo R
J Manag Care Spec Pharm; 2019 Oct; 25(10):1111-1123. PubMed ID: 31556817
[TBL] [Abstract][Full Text] [Related]
12. A Retrospective Database Study Comparing Diabetes-Related Medication Adherence and Health Outcomes for Mail-Order Versus Community Pharmacy.
Schwab P; Racsa P; Rascati K; Mourer M; Meah Y; Worley K
J Manag Care Spec Pharm; 2019 Mar; 25(3):332-340. PubMed ID: 30816817
[TBL] [Abstract][Full Text] [Related]
13. Impact of adherence to antidepressants on healthcare outcomes and costs among patients with type 2 diabetes and comorbid major depressive disorder.
Vega C; Becker RV; Mucha L; Lorenz BH; Eaddy MT; Ogbonnaya AO
Curr Med Res Opin; 2017 Oct; 33(10):1879-1889. PubMed ID: 28644095
[TBL] [Abstract][Full Text] [Related]
14. Clinical and economic outcomes among patients with diabetes mellitus initiating insulin glargine pen versus vial.
Grabner M; Chu J; Raparla S; Quimbo R; Zhou S; Conoshenti J
Postgrad Med; 2013 May; 125(3):204-13. PubMed ID: 23748521
[TBL] [Abstract][Full Text] [Related]
15. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O
Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
[TBL] [Abstract][Full Text] [Related]
16. Predictors of Change in Adherence Status from 1 Year to the Next Among Patients with Type 2 Diabetes Mellitus on Oral Antidiabetes Drugs.
Saundankar V; Peng X; Fu H; Ascher-Svanum H; Rodriguez A; Ali A; Slabaugh L; Young P; Louder A
J Manag Care Spec Pharm; 2016 May; 22(5):467-82. PubMed ID: 27123910
[TBL] [Abstract][Full Text] [Related]
17. The INITIATOR study: pilot data on real-world clinical and economic outcomes in US patients with type 2 diabetes initiating injectable therapy.
Thayer S; Wei W; Buysman E; Brekke L; Crown W; Grabner M; Raparla S; Quimbo R; Cziraky MJ; Hu W; Cuddihy R
Adv Ther; 2013 Dec; 30(12):1128-40. PubMed ID: 24293131
[TBL] [Abstract][Full Text] [Related]
18. Impact of Out-of-Pocket Pharmacy Costs on Branded Medication Adherence Among Patients with Type 2 Diabetes.
Bibeau WS; Fu H; Taylor AD; Kwan AY
J Manag Care Spec Pharm; 2016 Nov; 22(11):1338-1347. PubMed ID: 27783549
[TBL] [Abstract][Full Text] [Related]
19. The Association Between Adherence to Insulin Therapy and Health Care Costs for Adults with Type 2 Diabetes: Evidence from a U.S. Retrospective Claims Database.
Eby EL; Bajpai S; Faries DE; Haynes VS; Lage MJ
J Manag Care Spec Pharm; 2020 Sep; 26(9):1081-1089. PubMed ID: 32857656
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the relationship between quality measure adherence definitions and economic outcomes in commercial health plans: a retrospective diabetes cohort study.
Chinthammit C; Axon DR; Mollon L; Taylor AM; Pickering M; Black H; Warholak T; Campbell PJ
J Manag Care Spec Pharm; 2021 Jan; 27(1):64-72. PubMed ID: 33377445
[No Abstract] [Full Text] [Related]
[Next] [New Search]